<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897621</url>
  </required_header>
  <id_info>
    <org_study_id>18D.581</org_study_id>
    <nct_id>NCT03897621</nct_id>
  </id_info>
  <brief_title>The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery</brief_title>
  <official_title>The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery Based on Rotational Thromboelastometry (ROTEM®).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL.
      Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to
      reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot
      resolution. TXA is employed currently based on a surgeon's preference. The objective of this
      study is to quantitate the degree of fibrinolysis using rotational thromboelastometry (ROTEM)
      and investigate the role of TXA prophylaxis on blood loss in patients undergoing THA in a
      double-blind fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA
      prophylaxis is not necessary during THA. All patients, whether they receive TXA or normal
      saline, will not be at risk, as at this time no data exists to determine which approach is
      safer or more effective. This is the first study to compare TXA vs. placebo in a
      double-blinded, randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total hip arthroplasty (THA) is associated with moderate blood loss ranging from 300 to 2000
      mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure
      to reduce blood loss by inhibiting fibrinolysis. Most clinical studies reported potential
      benefit of the treatment demonstrated by less estimated blood loss (EBL), reduced
      hemoglobin/hematocrit (HH) change, and reduced transfused packed red blood cells (PRBC).
      However, bleeding complication may be affected more significantly by the degree of surgical
      trauma and comorbidity of patients than coagulation abnormality. Further, the frequency and
      severity of fibrinolysis during these procedures have not been well studied. Additionally,
      TXA administration may increase the tendency of postoperative venous thrombosis by inhibiting
      fibrinolysis in already prothrombotic patients. The objective of this study is to quantitate
      the degree of fibrinolysis using rotational thromboelastometry (ROTEM) and investigate the
      role of TXA prophylaxis on clinical outcome in patients undergoing THA in a double-blind
      fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA prophylaxis is not
      necessary during primary THA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blinded randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrinolysis</measure>
    <time_frame>after induction of anesthesia (baseline),</time_frame>
    <description>Fibrinolysis based on ROTEM parameter, defined as ML (maxium lysis) &gt;15%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrinolysis</measure>
    <time_frame>45 min after drug administration,</time_frame>
    <description>Fibrinolysis based on ROTEM parameter, defined as ML (maxium lysis) &gt;15%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrinolysis</measure>
    <time_frame>one hour after the end of surgery</time_frame>
    <description>Fibrinolysis based on ROTEM parameter, defined as ML (maxium lysis) &gt;15%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>during surgery (intraoperative)</time_frame>
    <description>amount of blood loss in milliliter during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood transfusion</measure>
    <time_frame>Intraoperative and up to 72-hour after surgery</time_frame>
    <description>Amount of Packed Red Blood Cells (PRBC) transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre- and postoperative hemoglobin level</measure>
    <time_frame>up to 72-hour after surgery</time_frame>
    <description>Pre and postoperative hemoglobin level in grams per deciliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound infection</measure>
    <time_frame>up to 72-hour after surgery</time_frame>
    <description>Incidence of wound infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma</measure>
    <time_frame>up to72-hour after surgery</time_frame>
    <description>Incidence of hematoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic events (PE, DVT).</measure>
    <time_frame>up to 72-hour after surgery</time_frame>
    <description>Incidence of thrombotic events (pulmonary embolism, deep vein thrombosis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coagulation; Intravascular</condition>
  <condition>Rotational Thromboelastometry</condition>
  <condition>Fibrinolysis; Hemorrhage</condition>
  <condition>Tranexamic Acid</condition>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).</description>
    <arm_group_label>tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The study population will include total of 200 adults (age range of 18 - 85 years) who
             are in the American Society of Anesthesiologists (ASA) Physical Status (PS) 1-3.
             Inclusion criteria are patients undergoing unilateral, primary, total hip
             arthroplasty.

        Exclusion Criteria:

          -  Exclusion criteria include patient's refusal, patients with history of significant
             coagulopathy or on anticoagulation therapy. Female patients who are pregnant or
             nursing will be excluded. In addition, patients with anemia (Hb &lt; 8 g/dL) or who
             received blood transfusion within one week before surgery will be excluded. Patient
             receiving subcutaneous heparin on the same day prior to surgery will be also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uzung Yoon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uzung Yoon, M.D.</last_name>
    <phone>2159100557</phone>
    <email>uzung.yoon@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uzung Yoon, M.D</last_name>
      <phone>215-910-0557</phone>
      <email>uzung.yoon@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wu Y, Yang T, Zeng Y, Si H, Cao F, Shen B. Tranexamic acid reduces blood loss and transfusion requirements in primary simultaneous bilateral total knee arthroplasty: a meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis. 2017 Oct;28(7):501-508. doi: 10.1097/MBC.0000000000000637.</citation>
    <PMID>28448319</PMID>
  </results_reference>
  <results_reference>
    <citation>Prieto HA, Vincent HK, Deen JT, Iams DA, Parvataneni HK. Tranexamic Acid Effectively Reduces Blood Loss and Transfusion Rates during Simultaneous Bilateral Total Knee Arthroplasty. J Knee Surg. 2018 Mar;31(3):270-276. doi: 10.1055/s-0037-1603333. Epub 2017 May 15.</citation>
    <PMID>28505683</PMID>
  </results_reference>
  <results_reference>
    <citation>Na HS, Shin HJ, Lee YJ, Kim JH, Koo KH, Do SH. The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM®) analysis. Anaesthesia. 2016 Jan;71(1):67-75. doi: 10.1111/anae.13270. Epub 2015 Nov 12.</citation>
    <PMID>26559015</PMID>
  </results_reference>
  <results_reference>
    <citation>Watts CD, Houdek MT, Sems SA, Cross WW, Pagnano MW. Tranexamic Acid Safely Reduced Blood Loss in Hemi- and Total Hip Arthroplasty for Acute Femoral Neck Fracture: A Randomized Clinical Trial. J Orthop Trauma. 2017 Jul;31(7):345-351. doi: 10.1097/BOT.0000000000000837.</citation>
    <PMID>28633147</PMID>
  </results_reference>
  <results_reference>
    <citation>Zufferey PJ, Lanoiselée J, Chapelle C, Borisov DB, Bien JY, Lambert P, Philippot R, Molliex S, Delavenne X; investigators of the PeriOpeRative Tranexamic acid in hip arthrOplasty (PORTO) Study. Intravenous Tranexamic Acid Bolus plus Infusion Is Not More Effective than a Single Bolus in Primary Hip Arthroplasty: A Randomized Controlled Trial. Anesthesiology. 2017 Sep;127(3):413-422. doi: 10.1097/ALN.0000000000001787.</citation>
    <PMID>28692467</PMID>
  </results_reference>
  <results_reference>
    <citation>Toledo P, McCarthy RJ, Hewlett BJ, Fitzgerald PC, Wong CA. The accuracy of blood loss estimation after simulated vaginal delivery. Anesth Analg. 2007 Dec;105(6):1736-40, table of contents.</citation>
    <PMID>18042876</PMID>
  </results_reference>
  <results_reference>
    <citation>Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997 Oct;37(10):1070-4.</citation>
    <PMID>9354828</PMID>
  </results_reference>
  <results_reference>
    <citation>Theusinger OM, Wanner GA, Emmert MY, Billeter A, Eismon J, Seifert B, Simmen HP, Spahn DR, Baulig W. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg. 2011 Nov;113(5):1003-12. doi: 10.1213/ANE.0b013e31822e183f. Epub 2011 Sep 14.</citation>
    <PMID>21918164</PMID>
  </results_reference>
  <results_reference>
    <citation>Ram GG, Suresh P, Vijayaraghavan PV. Surgeons often underestimate the amount of blood loss in replacement surgeries. Chin J Traumatol. 2014;17(4):225-8.</citation>
    <PMID>25098850</PMID>
  </results_reference>
  <results_reference>
    <citation>Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth. 2008 Jun;100(6):792-7. doi: 10.1093/bja/aen083. Epub 2008 Apr 24.</citation>
    <PMID>18440953</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Uzung Yoon</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>Rotational thromboelastometry</keyword>
  <keyword>Fibrinolysis</keyword>
  <keyword>viscoelastic essay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

